Cathrine Goberg Olsen, Vetle Nilsen Malmberg, Maria Fahlström, Karl Bjørnar Alstadhaug, Ingrid Kristine Bjørnå, Geir Julius Braathen, Geir Bråthen, Natasha Demic, Erika Hallerstig, Ineke Hogenesch, Morten Andreas Horn, Margitta T Kampman, Grethe Kleveland, Unn Ljøstad, Angelina Maniaol, Åse Hagen Morsund, Ola Nakken, Katrin Schlüter, Stephan Schuler, Elin Seim, Heidi Øyen Flemmen, Ole-Bjørn Tysnes, Trygve Holmøy, Helle Høyer
{"title":"Amyotrophic lateral sclerosis caused by the <i>C9orf72</i> expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status.","authors":"Cathrine Goberg Olsen, Vetle Nilsen Malmberg, Maria Fahlström, Karl Bjørnar Alstadhaug, Ingrid Kristine Bjørnå, Geir Julius Braathen, Geir Bråthen, Natasha Demic, Erika Hallerstig, Ineke Hogenesch, Morten Andreas Horn, Margitta T Kampman, Grethe Kleveland, Unn Ljøstad, Angelina Maniaol, Åse Hagen Morsund, Ola Nakken, Katrin Schlüter, Stephan Schuler, Elin Seim, Heidi Øyen Flemmen, Ole-Bjørn Tysnes, Trygve Holmøy, Helle Høyer","doi":"10.1080/21678421.2024.2405118","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The most common genetic cause of amyotrophic lateral sclerosis (ALS) is the <i>C9orf72</i> expansion. A high incidence of this expansion has been detected in Sweden and Finland. This Norwegian population-based study aimed to identify the prevalence, geographic distribution, ancestry, and relatedness of ALS patients with a <i>C9orf72</i> expansion (C9<sub>pos</sub>). Further, we compared C9<sub>pos</sub> and C9<sub>neg</sub> patients' clinical presentation, family history of ALS and other neurodegenerative disorders, and sociodemographic status.</p><p><strong>Methods: </strong>We recruited ALS patients from all 17 Departments of neurology in Norway. Blood samples and questionnaires regarding clinical characteristics, sociodemographic status and family history of ALS, and other neurodegenerative disorders were collected. The <i>C9orf72</i> expansion was examined for all patients.</p><p><strong>Results: </strong>The study enrolled 500 ALS patients, 8.8% of whom were C9<sub>pos</sub>, with half being sporadic ALS cases. The proportion of C9<sub>pos</sub> cases differed between regions, ranging from 17.9% in the Northern region to 1.9% in the Western region. The majority of C9<sub>pos</sub> patients had non-Finnish European descent and were not closely related. C9<sub>pos</sub> patients exhibited a significantly shorter mean survival time, had a higher frequency of relatives with ALS or dementia, and were more often unmarried/single and childless than C9<sub>neg</sub> patients.</p><p><strong>Conclusion: </strong>C9<sub>pos</sub> patients constitute a large portion of the Norwegian ALS population. Ancestry and relatedness do not adequately explain regional differences. Relying on clinical information to identify C9<sub>pos</sub> patients has proven to be challenging. Half of C9<sub>pos</sub> patients were reported as having sporadic ALS, underlining the importance of carefully assessing family history and the need for genetic testing.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"132-140"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2405118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The most common genetic cause of amyotrophic lateral sclerosis (ALS) is the C9orf72 expansion. A high incidence of this expansion has been detected in Sweden and Finland. This Norwegian population-based study aimed to identify the prevalence, geographic distribution, ancestry, and relatedness of ALS patients with a C9orf72 expansion (C9pos). Further, we compared C9pos and C9neg patients' clinical presentation, family history of ALS and other neurodegenerative disorders, and sociodemographic status.
Methods: We recruited ALS patients from all 17 Departments of neurology in Norway. Blood samples and questionnaires regarding clinical characteristics, sociodemographic status and family history of ALS, and other neurodegenerative disorders were collected. The C9orf72 expansion was examined for all patients.
Results: The study enrolled 500 ALS patients, 8.8% of whom were C9pos, with half being sporadic ALS cases. The proportion of C9pos cases differed between regions, ranging from 17.9% in the Northern region to 1.9% in the Western region. The majority of C9pos patients had non-Finnish European descent and were not closely related. C9pos patients exhibited a significantly shorter mean survival time, had a higher frequency of relatives with ALS or dementia, and were more often unmarried/single and childless than C9neg patients.
Conclusion: C9pos patients constitute a large portion of the Norwegian ALS population. Ancestry and relatedness do not adequately explain regional differences. Relying on clinical information to identify C9pos patients has proven to be challenging. Half of C9pos patients were reported as having sporadic ALS, underlining the importance of carefully assessing family history and the need for genetic testing.